Targetable Treatment Resistance in Thyroid Cancer with Clonal Hematopoiesis

Vera Tiedje,Pablo Sanchez Vela,Julie L. Yang,Brian R. Untch,Laura Boucai,Aaron J. Stonestrom,Alberto Bueno Costa,Sebastia Franch Exposito,Avi Srivastava,Marina Kerpelev,Jillian Greenberg,Matthew Wereski,Amanda Kulick,Kevin Chen,Tianyue Qin,Soo-Yeon Im,Aishwarya Krishnan,Anthony R. Martinez Benitez,Raquel Pluvinet,Merve Sahin,Kamal Menghrajani,Gnana P. Krishnamoorthy,Elisa De Stanchina,Ahmet Zehir,Rahul Satija,Jeffrey Knauf,Robert Bowman,Manel Esteller,Sean M. Devlin,Michael Berger,Richard Koche,James A Fagin,Ross Levine

DOI: https://doi.org/10.1101/2024.10.10.617685

2024-10-11

Abstract:Anaplastic thyroid cancer (ATC) is a clinically aggressive malignancy with a dismal prognosis. Combined BRAF/MEK inhibition offers significant therapeutic benefit in patients with BRAFV600E-mutant ATCs. However, relapses are common and overall survival remains poor. Compared with differentiated thyroid cancer, a hallmark of ATCs is significant infiltration with myeloid cells, particularly macrophages. ATCs are most common in the aging population, which also has an increased incidence of TET2-mutant clonal hematopoiesis (CH). CH-mutant macrophages have been shown to accelerate CH-associated pathophysiology including atherosclerosis. However, the clinical and mechanistic contribution of CH-mutant clones to solid tumour biology, prognosis and therapeutic response has not been elucidated. Here we show that TET2-mutant CH is enriched in the tumour microenvironment of patients with solid tumours and associated with adverse prognosis in ATC patients. We find that Tet2-mutant macrophages selectively infiltrate mouse BrafV600E-mutant ATC and that their overexpression of Tgfβ-family ligands mediates resistance to BRAF/MEK inhibition. Importantly, inhibition of Tgfβ signaling restores sensitivity to MAPK pathway inhibition, opening a path for synergistic strategies to improve outcomes of patients with ATCs and concurrent CH.

Cancer Biology